Ca-AKG vs FOXO4-DRI
A side-by-side research comparison of Ca-AKG and FOXO4-DRI across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Ca-AKG | FOXO4-DRI |
|---|---|---|
| Full name | Calcium Alpha-Ketoglutarate | FOXO4-D-Retro-Inverso Peptide (Senolytic) |
| Category | Anti-Aging | Anti-Aging |
| Status | Dietary compound (research ongoing) | Research compound |
| Mechanism | Alpha-ketoglutarate is a key TCA-cycle intermediate and a cofactor for enzymes involved in energy metabolism, collagen synthesis, and epigenetic regulation (it influences DNA/histone demethylases). Supplementation aims to restore age-related declines. | Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism. |
| Molecular weight | ~204 Da (AKG portion) | ~4,500 Da |
| Half-life | Short; rapidly metabolized | 12-24 hours (D-amino acid stability) |
| Bioavailability | Oral | Moderate (SubQ) |
| Typical dose | 1-3 g per day | 5-10 mg/kg (animal studies) |
| Frequency | 1-2x daily | 3x per week for 3 weeks |
| Route | Oral | Subcutaneous |
Ca-AKG reported benefits
- Supports cellular energy metabolism
- Studied for reduced biological-aging markers
- May lower inflammation
- Supports collagen synthesis
FOXO4-DRI reported benefits
- Selective senescent cell elimination
- Potential aging reversal
- Improved tissue function
- Reduced inflammatory burden
- Hair regrowth (mice)
Related comparisons
Research and educational reference only. Not medical advice.